National Center for the Medical Consequences of Spinal Cord Injury, James J Peters VA Medical Center, Bronx, NY 10468, United States; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
Research and Development, James J Peters VA Medical Center, Bronx, NY 10468, United States; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
Brain Res. 2019 Sep 15;1719:194-207. doi: 10.1016/j.brainres.2019.05.031. Epub 2019 May 23.
Alzheimer's disease (AD) is a common neurodegenerative disorder that presents with cognitive impairment and behavioral disturbance. Approximately 5.5 million people in the United States live with AD, most of whom are over the age of 65 with two-thirds being woman. There have been major advancements over the last decade or so in the understanding of AD neuropathological changes and genetic involvement. However, studies of sex impact in AD have not been adequately integrated into the investigation of disease development and progression. It becomes indispensable to acknowledge in both basic science and clinical research studies the importance of understanding sex-specific differences in AD pathophysiology and pathogenesis, which could guide future effort in the discovery of novel targets for AD. Here, we review the latest and most relevant literature on this topic, highlighting the importance of understanding sex dimorphism from a molecular perspective and its association to clinical trial design and development in AD research field.
阿尔茨海默病(AD)是一种常见的神经退行性疾病,表现为认知障碍和行为障碍。大约有 550 万美国人患有 AD,其中大多数人年龄在 65 岁以上,三分之二为女性。在过去的十年左右,人们对 AD 的神经病理学变化和遗传参与有了重大的认识。然而,AD 中性别影响的研究并没有充分纳入疾病发展和进展的研究中。在基础科学和临床研究中认识到 AD 病理生理学和发病机制中性别差异的重要性是必不可少的,这可以为 AD 的新型靶点的发现提供指导。在这里,我们回顾了这个主题的最新和最相关的文献,强调了从分子角度理解性别二态性的重要性,以及它与 AD 研究领域临床试验设计和开发的关联。